CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop immune-privileged cardiac progenitor cells for treating dilated cardiomyopathy. By creating and converting these cells into cardioblasts, the project seeks to improve heart repair mechanisms in damaged areas, potentially leading to novel treatment protocols.
Dilated cardiomyopathy (DCM) is the second most common cause of heart failure, currently treated with drugs that delay progress towards heart transplantation.
There are currently many attempts to treat DC with stem cells or their extracellular vesicles or AAV vectors: none reached efficacy so far.
The applicant has a long track record in cell and gene therapy for muscular dystrophy.
He pioneered systemic intra-arterial transplantation of mesoangioblasts (blood vessel-derived progenitors) and, th…
OSPEDALE SAN RAFFAELE SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, ROMA RM
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
